There are 27 generic pharmaceutical enterprises authorized by MPP in the world.
Beijing News (reporter Zhang Xiulan) on January 20, local time, the Geneva pharmaceutical patent pool (MPP) announced through its official website that 27 generic pharmaceutical enterprises around the world were authorized to produce molnupiravir or API of mosadon covid-19 oral drug, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Langhua pharmaceutical, Longze pharmaceutical and Desano pharmaceutical. On January 21, the share prices of the above-mentioned enterprises rose significantly. What are the origins of the five Chinese enterprises behind the MPP agreement?
27 enterprises worldwide are authorized by MPP
According to the news released by MPP, the organization has signed agreements with 27 generic pharmaceutical enterprises around the world, which are authorized to produce molnupiravir or API of covid-19 oral drug of MSD and supply it to 105 low-income countries and regions around the world. Molnupiravir is the world’s first oral antiviral drug approved for the treatment of mild to moderate covid-19 in adults. This authorization is based on the voluntary license agreement signed between MPP and MSD in October 2021.
The 27 authorized enterprises are distributed in 11 countries and regions around the world, including Bangladesh, China, India, South Korea, etc. Among them, 5 enterprises produce APIs, 13 enterprises produce APIs and drugs, and 9 enterprises produce drugs.
The five authorized Chinese enterprises are Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Langhua pharmaceutical, Longze pharmaceutical and Desano pharmaceutical. Among them, Langhua pharmaceutical only obtained the API production authorization, and the other four enterprises obtained the API and drug production authorization. However, according to the supply regions announced by MPP, China is not included in this list.
As soon as the news came out, on January 21, the stock prices of authorized Chinese enterprises rose one after another, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) opened the trading limit, and then opened the board. As of the close, Brightgene Bio-Medical Technology Co.Ltd(688166) rose by the limit, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) rose by 5.98%, Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (participation in Longze pharmaceutical) rose by 10.79%, and the Hong Kong listed company viabio (Langhua pharmaceutical is its holding subsidiary) rose by 16.83% at the time of publishing.
MPP also pointed out that covid-19 is still listed as a public health emergency of international concern by the World Health Organization (who). Therefore, in this license, MSD, Ridgeback and Emory University, which invented the drug, will not receive royalties for molnupiravir sales from the license Licensor.
In addition to MSD, Pfizer, another pharmaceutical company with covid-19 drugs, also signed a license agreement with MPP. In November 2021, Pfizer issued a statement and signed an agreement with MPP. Once authorized by the regulatory authority, generic drug enterprises will be allowed to produce cheap versions of anti-covid-19 drugs for 95 low-income and middle-income countries.
how are the five Chinese enterprises coming from?
Among the five authorized enterprises, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) has the largest volume. Calculated according to the closing price on January 21, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) has a total market value of more than 131.7 billion yuan. Its direct operations include pharmaceuticals, medical devices and medical diagnosis, medical and health services, and it covers the pharmaceutical business field by participating in Sinopharm holdings. Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) is also one of the largest antimalarial drug manufacturers in the world. It has become an antimalarial drug supplier of the global fund, UNICEF, who and drug procurement centers in African countries. It also has an international layout. It has a mature sales network and upstream and downstream customer resources in English and French speaking areas in sub Saharan Africa.
Brightgene Bio-Medical Technology Co.Ltd(688166) has been engaged in the R & D and production of pharmaceutical intermediates, APIs and preparations with high technical barriers. In the field of generic drugs, Brightgene Bio-Medical Technology Co.Ltd(688166) has mastered the production core technology of more than 40 high-end chemical drugs, including entecavir, and its products have been sold in dozens of countries around the world. Some products help customers achieve the first generic listing in a specific market.
The main products of Longze pharmaceutical include antiviral, antidepressant and anti neuralgia preparations, raw materials and intermediates. As one of the world’s most important suppliers of anti aids products, lung Ze Pharmaceutical provides support to every year around 4 million AIDS patients including China.
Langhua pharmaceutical, a subsidiary of Weiya biological holdings, a Hong Kong listed company, is committed to providing partners with cdmo one-stop solutions for small molecule drugs, from APIs to preparations, from preclinical to commercial supply, and providing small molecule imitation APIs for the global market. It is a global leader in quinolones, spironolactones, olanzapine Major manufacturers of antiviral and other APIs.
In 1996, the company was based on the development of anti AIDS drugs. It was one of the first enterprises in China to develop anti HIV drugs and obtain approval for the production of such drugs. In the international anti AIDS market, 4 preparations have been approved by WHO, and 2 preparations have been approved by the US Food and Drug Administration (FDA).
